IGC Pharma Shares More Phase 2 Interim Results on IGC-AD1's Cognitive Benefits for Alzheimer's

IGC Pharma, based in Potomac, Maryland, has shared new interim results from its ongoing Phase 2 clinical trial of IGC-AD1, which targets agitation in Alzheimer’s patients as its main goal while also evaluating cognition. Interim analysis indicates cognitive enhancements in the treatment group compared to the placebo group, suggesting a promising step towards potential disease-modifying therapy.

These findings reflect earlier preclinical studies where amyloid plaque aggregation was reduced by about 20%, and spatial memory improved by approximately 50% in Alzheimer's cell lines and mouse models.

### Cognitive Enhancements Indicate Disease Progression

Alzheimer's disease is characterized by cognitive decline, including memory, attention, language, and reasoning, due to amyloid plaques and tau tangles. The interim results from the trial showed that participants in the active treatment group, who received IGC-AD1 twice daily for six weeks, experienced an average 8% improvement on the Mini-Mental State Examination (MMSE), a recognized clinical tool for cognitive assessment. In contrast, the placebo group did not exhibit any improvement during the same period.

This data, along with previous preclinical studies, provides a strong basis for future trials that will emphasize cognition as the primary endpoint and further explore IGC-AD1’s potential to modify the disease process.

Ram Mukunda, CEO of IGC Pharma, remarked on the cognitive improvements observed in the interim results, emphasizing that they align with preclinical evidence of IGC-AD1's active ingredients affecting amyloid plaques and spatial memory. Although agitation remains the primary focus of the Phase 2 trial, these results increase confidence in IGC-AD1’s potential to address Alzheimer’s broader pathology. For patients and caregivers, this could mean improved care, and for investors, it represents a substantial opportunity in a growing market.

### Focus on Reducing Agitation in Alzheimer's Patients

Agitation is a severe symptom that impacts up to 76% of Alzheimer’s patients, accelerating disease progression, adding to caregiver stress, and leading to higher hospitalization rates. Previous interim results have shown that IGC-AD1 significantly reduces agitation compared to placebo, with improvements noticed as early as two weeks. Unlike existing therapies, which often take 6–10 weeks to show effectiveness and come with a black box warning, IGC-AD1 offers rapid symptom relief with a favorable safety profile, positioning it as a unique potential treatment for managing Alzheimer’s agitation.

Alzheimer’s disease currently affects 6.7 million Americans, and the global market for Alzheimer’s treatment is projected to surpass $50 billion by 2025. The unique profile of IGC-AD1—combining rapid onset for agitation with potentially disease-modifying effects—positions it as a highly differentiated therapy in this growing field. Mukunda continued, "These developments aim to advance IGC-AD1 toward commercialization with additional trials and regulatory approvals, potentially delivering transformative patient care and creating significant value for our investors."

### About IGC Pharma

IGC Pharma is an AI-powered, clinical-stage biotechnology company dedicated to developing innovative treatments for Alzheimer’s disease and improving patient care with fast-acting, safe, and effective solutions. Its portfolio includes the TGR family, such as TGR-63, targeting amyloid plaques, a hallmark of Alzheimer’s. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks.

The company’s leading therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently undergoing a Phase 2 trial for agitation in dementia related to Alzheimer’s. Clinical data suggest IGC-AD1 has the potential to revolutionize patient care by providing faster and more effective relief than traditional medications. Additionally, IGC Pharma employs AI models designed to predict potential biomarkers for early Alzheimer’s detection, optimize clinical trials, and forecast receptor affinity, among other capabilities. With 28 patent filings and a firm commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer’s and related conditions.